BICUSAN 50mg. 30 tablets
BICUSAN 50mg. 30 tablets
Bicusan is a medicine that inhibits certain hormones / androgens / in the body and thus prevents the development of prostate tumors. Bicusan 50 mg is administered to treat advanced prostate cancer in combination with treatment with an LHRH analogue, or surgical castration.
BEFORE YOU TAKE BICUSAN
Bicusan not apply to:
- Women and children
- Hypersensitivity to the active ingredients of the product
- Co-administration with terfenadine, astemizole, cisapride
Take care with Bicusan:
Bicusan processed largely in the liver. In subjects with severe hepatic impairment output can be fun and lead to the accumulation of the product. In these patients, the product should be used with caution and to conduct periodic assessment of liver function due to possible changes in the liver. More likely is that to occur in the first six months of treatment.
In patients with established objective disease progression and increased prostate specific antigen Bicusan treatment should be discontinued.
It has been shown that the product inhibits certain enzymes in the liver, and therefore, caution should be used when co-administered with drugs that are processed preferably by means of this system.
Pregnancy and lactation
Bicusan not apply to women.
DRIVE AND USE MACHINES
It is unlikely that the product affect driving or operating machinery. However, it can not be excluded drowsiness, which requires attention.
DETAILS OF OTHER SUBSTANCES
This product contains lactose, which makes it unsuitable for patients with lactase deficiency, galactosemia or glucose / galactose malabsorption.
HOW TO TAKE BICUSAN
Adult males including the elderly: one tablet of 50 mg once daily. Treatment should start at least 3 days prior to treatment with the LHRH analogue or surgical castration.
The product should be administered continuously for at least two years or until disease progression.
Patients with renal impairment:
There is no need for dosage adjustment in patients with renal impairment.
Patients with hepatic impairment:
There is no need for dosage adjustment in patients with mild hepatic impairment. Those with moderate to severe damage can be observed increased accumulation of the product.
POSSIBLE SIDE EFFECTS
Immune system disorders:
Uncommon - hypersensitivity reactions, including. angioneurotic edema and urticaria.
Uncommon - depression
Respiratory, thoracic and mediastinal disorders:
Uncommon - interstitial lung disease
Common - diarrhea, nausea
Rare - vomiting
Common - liver changes
Very rare - liver failure
Skin and subcutaneous tissue disorders:
Common - persistent itching
Rare - dry skin
Renal and urinary disorders:
Uncommon - blood in urine
Reproductive system and breast disorders:
Very common - breast tenderness, breast enlargement
General disorders and administration site conditions:
Very common - hot flushes
Common - fatigue
The active ingredient is bicalutamide.
The other ingredients are lactose monohydrate, povidone, crospovidone, sodium lauryl sulphate, magnesium stearate.
Composition of the tablet coating: lactose monohydrate, hypromellose, titanium dioxide, macrogol